Number of Current Board & Advisor Roles 22
Number of Founded Organizations 1
  • Investor Type  Investment Partner

Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health.

Since joining KPCB in 2005, Beth has incubated five companies and serves on the board of directors of 3-V Biosciences,

Armo Biosciences, Atara, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO.

Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc.

Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals.

Beth received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.

Number of Current Jobs 3
Number of Past Jobs 3
Beth Seidenberg has 3 current jobs including Managing Director at Westlake Village BioPartners, General Partner at Kleiner Perkins, and Chair of Board at Kate Therapeutics. Additionally, Beth Seidenberg has had 3 past jobs including Senior Executive, Research and Development at Bristol-Myers Squibb.
Organization Name  
Title At Company  
Start Date  
End Date  
Bristol-Myers Squibb
Senior Executive, Research and Development——
Amgen Ventures
Vice President, Global Development, and Chief Medical Officer——
Merck
Senior Executive - R&D——
Number of Current Board & Advisor Roles 22
Beth Seidenberg holds 22 board and advisor roles including Board Member at Electra Therapeutics, Board Member at Vera Therapeutics, and Board Member at Neuron23.
Number of Events 2
Beth Seidenberg has participated in 2 events. They most recently attended, or will attend, Techcrunch Disrupt SF 2015 on Sep 19, 2015.
Number of News Articles 112
News•Apr 21, 2020
News•Jun 21, 2019
San Fernando Business Journal — Venture Capital Firm Keynotes Bioscience Alliance Event
News•Jun 21, 2019
San Fernando Business Journal — Venture Capital Firm Keynotes Bioscience Alliance Event
News•Oct 30, 2018
News•Sep 14, 2018
News•Sep 6, 2018